New drug cocktail aims to outsmart lung cancer resistance
NCT ID NCT07285148
First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This study tests a new drug (ANS014004) combined with a standard targeted therapy (EGFR-TKI) in people with advanced EGFR-mutated non-small cell lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially when the cancer has become resistant to treatment. About 253 adults will take part across two phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center David H, Koch Center lor Cancer Care
New York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.